In our penultimate JP Morgan 2023 interview, pharmaphorum editor-in-chief Jonah Comstock caught up with Lisa Yañez, CEO of Aerami Therapeutics, at the Fairmont Hotel.
There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the N
Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients t
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte